首页> 外文期刊>Pediatric Pulmonology >Efficacy of Oral Corticosteroids in the Treatment of Acute Wheezing Episodes in Asthmatic Preschoolers: Systematic Review With Meta-Analysis
【24h】

Efficacy of Oral Corticosteroids in the Treatment of Acute Wheezing Episodes in Asthmatic Preschoolers: Systematic Review With Meta-Analysis

机译:口服糖皮质激素治疗哮喘学龄前儿童急性喘息发作的疗效:荟萃分析的系统评价

获取原文
获取原文并翻译 | 示例
           

摘要

Rationale: Systemic corticosteroids (SCS) are used for treat preschoolers with acute asthma or wheezing exacerbations, with conflicting results. Objective: To evaluate the effectiveness of oral corticosteroids (OCS) compared to placebo in preschoolers presenting with acute asthma/wheezing exacerbations. Methods: Five electronic databases were searched for all placebo-controlled, randomized clinical trials of OCS in children <6 years of age presenting with recurrent wheezing/asthma exacerbations of any severity. Primary outcomes were hospitalizations, unscheduled emergency department (ED) visits in following month, need of additional OCS courses, and length of stay (ED or hospital). Results: Eleven studies met inclusion criteria (n = 1,733); four were conducted on an outpatient basis, five in inpatients, and two in the ED. Significant heterogeneity was found when pooling all studies, and thus analysis was stratified by trial setting. Among the outpatient studies, children who received OCS had a higher hospitalization rate (RR: 2.15[95% CI = 1.08-4.29], I-2 = 0%) compared to those to received placebo. Among the ED studies, children who received OCS had a lower risk of hospitalization (RR: 0.58[0.37-0.92], I-2 = 0%). Among the inpatient studies, children who received OCS needed fewer additional OCS courses than those on placebo (RR: 0.57 [0.40-0.81], I-2 = 0%). Conclusions: Treatment with OCS in the ED or hospital may be beneficial in toddlers and preschoolers with frequent asthma/wheezing exacerbations. However, more studies are needed before OCS can be broadly recommended for this age group. Future trials should be carefully designed to avoid bias and according to our findings regarding administration setting. (C) 2016 Wiley Periodicals, Inc.
机译:理由:全身性皮质类固醇(SCS)用于治疗患有急性哮喘或喘息加重的学龄前儿童,其结果相互矛盾。目的:评价口服皮质类固醇(OCS)与安慰剂相比在患有急性哮喘/喘息加剧的学龄前儿童中的有效性。方法:在五个电子数据库中搜索了所有6岁以下患有任何严重程度的喘息/哮喘加重发作的儿童的OCS安慰剂对照,随机临床试验。主要结果是住院,下个月急诊急诊就诊,需要额外的OCS课程以及住院时间(急诊或住院)。结果:11项研究符合纳入标准(n = 1,733);四例在门诊进行,五例在住院,二例在急诊。汇总所有研究时发现了显着的异质性,因此按试验环境对分析进行了分层。在门诊研究中,与接受安慰剂的孩子相比,接受OCS的孩子的住院率更高(RR:2.15 [95%CI = 1.08-4.29],I-2 = 0%)。在ED研究中,接受OCS的儿童住院风险较低(RR:0.58 [0.37-0.92],I-2 = 0%)。在住院研究中,接受OCS的儿童比接受安慰剂的儿童需要更多的OCS疗程(RR:0.57 [0.40-0.81],I-2 = 0%)。结论:在急诊部或医院中使用OCS进行治疗可能对哮喘/喘息加剧的学步儿童和学龄前儿童有益。但是,要广泛推荐该年龄段的OCS,还需要进行更多研究。应仔细设计未来的试验,以免产生偏差,并根据我们有关给药设置的发现。 (C)2016威利期刊公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号